Company News


Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia

Development program for VLX-1005, a novel small molecule 12-LOX inhibitor, awarded Fast Track designation by US Food and Drug Administration

FREDERICK, Md., June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat serious immuno-inflammatory diseases with significant unmet medical needs, today announced favorable results from the Company’s Phase 1 clinical program for VLX-1005, a novel 12-LOX inhibitor being developed for the treatment and prevention of heparin-induced thrombocytopenia and thrombosis (HIT). Veralox also announced that VLX-1005 has been awarded Fast Track Designation by the U.S. Food and Drug Administration (FDA).

“Completion of our Phase 1 study for VLX-1005 together with announcement of Fast Track Designation for this program represent important milestones that reflect the new levels of momentum we are achieving with our clinical strategy at Veralox,” said Michael Hanna, Chief Medical Officer at Veralox. “We look forward to continuing our development of VLX-1005 to address the underlying pathology of HIT, a disease that has not seen innovation in available therapies in over 20 years.”

Veralox completed a Phase 1a study consisting of a single ascending dose (SAD) portion and a multiple ascending dose (MAD) portion that was designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of VLX-1005. In this study VLX-1005 was found to be well tolerated with no reports of serious adverse events (SAEs), dose-limiting toxicities (DLTs) or discontinuations; adverse events (AEs) were infrequent and mild. Data analyses revealed dose linear increases in key PK metrics approaching dose proportionality with no upper limits on tolerability to the maximum dose tested.

Veralox also completed a Phase 1b drug-drug interaction (DDI) study of VLX-1005 in conjunction with argatroban, an anticoagulant that is approved for the treatment of HIT in the U.S. This study was designed to evaluate the effects of coadministration of VLX-1005 and argatroban on subject safety and on a range of exploratory biomarkers. The study showed that co-administration of VLX-1005 with argatroban was well tolerated with no SAEs; AEs were infrequent and mild. Preliminary analysis of the PK and PD (as measured by APTT) data revealed no evidence of DDI.

The FDA granted Fast Track designation for the VLX-1005 program on May 27, 2022, following an End-of-Phase 1 meeting with the Agency. The company will use the results of the successful Phase 1 studies as well as the standards inherent in Fast Track designation and previously announced Orphan Drug designation to finalize the design of the planned Phase 2 clinical program for VLX-1005 in HIT.

About Veralox Therapeutics
VERALOX Therapeutics Inc. ( is the clinical leader in developing first-in-class therapeutics targeting 12-lipoxygenase, pioneering a new class of therapies that treat the underlying pathologies of serious immune-inflammatory diseases with unmet medical needs. The company’s lead candidate, VLX-1005, is in development for the treatment of patients with heparin-induced thrombocytopenia (HIT). Second generation therapeutic products are under development for type 1 diabetes and other immune-mediated and inflammatory diseases.

Media contact:
Bill Berry
Berry & Company Public Relations
212 253 8881

SOURCE Veralox Therapeutics